Immune Therapeutics, Inc. (OTCQB: IMUN) made two additions to its board recently, and if experience and knowledge are said to be key indicators of effectiveness, employees and shareholders alike have reason to be elated with the news. Dr. Clifford A. Selsky and Paul Akin carry a wealth of experience in their respective areas of influence and bolster the company’s leadership assets going forward. Paul Akin brings financial experience developed across his prior operating and board roles to the IMUN board. Dr. Selsky offers a vital perspective as a scientist, physician and patient advocate. The company intends to use their respective know-how on its road toward pursuing financial growth while developing and commercializing novel, patented therapies for life-threatening diseases by activating the body’s immune system.
Noreen Griffin, CEO of Immune Therapeutics, noted in a press release, “Paul Akin and Dr. Selsky’s breadth of knowledge and experience will provide invaluable insight to Immune as we continue to grow the business and strive to deliver innovative therapies in emerging nations.”
Clifford A. Selsky, PhD, MD, has been a pediatrician for the past 20 years, earning his PhD in microbiology and molecular genetics at the University of Miami School of Medicine prior to completing DNA repair research studies at Harvard School of Public Health and Stanford University.
Paul Akin brings more than 25 years of leadership experience to IMUN’s board. Akin played an important role in the strategic planning and coordination of market penetration, capitalization and expansion. He currently serves as the CEO and executive chairman of San Francisco-based Collier Warehouse Group, where he’s fostered annual double-digit growth rates during his tenure.
Immune Therapeutics, Inc. is a biotechnology company with a leading portfolio of immunotherapy technologies aimed at capturing the promise of the immune system for improving the treatment of cancer, HIV/Aids and other chronic and autoimmune diseases. The company is currently looking into investigations of its programs for met-enkephalin (MENK) and low dose naltrexone (LDN), or Lodonal™ – as treatments for many underserved indications.
In February, leading independent equity research and corporate access firm SeeThruEquity announced that it has initiated coverage on Immune Therapeutics with a 12-month price target of $0.61.
Learn more by visiting www.immunetherapeutics.com
Let us hear your thoughts: Immune Therapeutics, Inc. Message Board
